| 1 |
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1)：1-12.
|
| 2 |
Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies[J]. BMJ, 2008, 336(7653): 1106-1110.
|
| 3 |
Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009)[DB/OL]. Oxford Centre for Evidence-Based Medicine, 2009 [2021-12-20].
URL
|
| 4 |
Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17(Suppl 2) : S44-S57.
|
| 5 |
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403.
|
| 6 |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1): 35-43.
|
| 7 |
Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience[J]. Eur J Gastroenterol Hepatol, 2014, 26(2): 200-204.
|
| 8 |
Audet M, Panaro F, Piardi T, et al. Are the Hangzhou criteria adaptable to hepatocellular carcinoma patients for liver transplantation in Western countries？[J]. Liver Transpl, 2009, 15(7): 822-823.
|
| 9 |
Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma[J]. PLoS One, 2014, 9(3): e93128.
|
| 10 |
Xiao GQ, Yang JY, Yan LN. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(6)：588-595.
|
| 11 |
徐骁，杨家印，钟林，等. 肝癌肝移植"杭州标准"的多中心应用研究——1163例报道[J]. 中华器官移植杂志，2013, 34 (9): 524-527.
|
| 12 |
Xu X, Lu D, Ling Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6)：1035-1041.
|
| 13 |
Hu Z, Wang W, Li Z, et al. Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis[J]. Liver Transpl, 2012, 18(11): 1316-1323.
|
| 14 |
Zhang X, Li C, Wen T, et al. Outcomes of salvage liver transplantation and re-resection/radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: a new surgical strategy based on recurrence pattern[J]. Dig Dis Sci, 2018, 63(2)：502-514.
|
| 15 |
Bhangui P, Saigal S, Gautam D, et al. Incorporating tumor biology to predict hepatocellular carcinoma recurrence in patients undergoing living donor liver transplantation using expanded selection criteria[J]. Liver Transpl, 2021, 27(2): 209-221.
|
| 16 |
Liang HR, Hsieh CE, Lin KH, et al. Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size[J]. BMC Surg, 2021, 21(1): 401.
|
| 17 |
Alim A, Erdogan Y, Dayangac M, et al. Living donor liver transplantation: the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria[J]. Cancer Control, 2021, 28：10732748211011960.
|
| 18 |
Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-e22.
|
| 19 |
Berenguer M, Burra P, Ghobrial M, et al. Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS Transplant Oncology Consensus Conference[J]. Transplantation, 2020, 104(6): 1143-1149.
|
| 20 |
Chapman WC, Garcia-Aroz S, Vachharajani N, et al. Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions[J]. J Am Coll Surg, 2017, 224(4): 610-621.
|
| 21 |
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
|
| 22 |
Jiang G, Ling S, Zhan Q, et al. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation[J]. Transplant Rev (Orlando), 2021, 35(2)：100606.
|
| 23 |
Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 151(6): 1155-1163.
|
| 24 |
Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma[J]. Int J Hepatol, 2013, 2013: 419302.
|
| 25 |
Klompenhouwer EG, Dresen RC, Verslype C, et al. Safety and efficacy of transarterial radioembolisation in patients with intermediate or advanced stage hepatocellular carcinoma refractory to chemoembolisation[J]. Cardiovasc Intervent Radiol, 2017, 40(12): 1882-1890.
|
| 26 |
Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient？[J]. Am J Transplant, 2020, 20(3): 879-883.
|
| 27 |
Schwacha-Eipper B, Minciuna I, Banz V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020, 72(4): 1488-1490.
|
| 28 |
Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66：101386.
|
| 29 |
Gunsar F. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Exp Clin Transplant, 2017, 15(Suppl 2): 59-64.
|
| 30 |
Chen YY, Chen CL, Lin CC, et al. Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: a case-control study[J]. Cancers (Basel), 2021, 13(18): 4584.
|
| 31 |
Han B, Ding H, Zhao S, et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: a retrospective, case control study[J]. Front Oncol, 2020, 10: 562103.
|
| 32 |
Graziadei I, Zoller H, Fickert P, et al. Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)[J]. Wien Klin Wochenschr, 2016, 128(19-20): 679-690.
|
| 33 |
Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma[J]. J Hepatol, 2011, 55(4): 814-819.
|
| 34 |
Samaylova ML, Dodge JL, Yao FY, et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation[J]. Liver Transpl, 2014, 20(8): 937-944.
|
| 35 |
Mehta N, Dodge JL, Grab JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time[J]. Hepatology, 2020, 71(3): 943-954.
|
| 36 |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: liver transplantation[J]. J Hepatol, 2016, 64(2): 433-485.
|
| 37 |
Sastre J, Díaz-Beveridge R, García-Foncillas J, et al. Clinical Guideline SEOM: hepatocellular carcinoma[J]. Clin Transl Oncol, 2015, 17(12): 988-995.
|
| 38 |
Zhan QF, Ling SB, Deng YN, et al. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: a multicenter study from China[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4)：349-357.
|
| 39 |
Qu LS, Liu JX, Zhu J, et al. Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis B viral load[J]. Ann Hepatol, 2017, 16(3): 412-420.
|
| 40 |
Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 33(10): 1104-1112.
|
| 41 |
Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function[J]. Intern Med, 2009, 48(1): 11-17.
|
| 42 |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
|
| 43 |
Hu TH, Chen CL, Lin CC, et al. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation[J]. Transplantation, 2014, 97 Suppl 8: S53-S59.
|
| 44 |
Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29): 3647-3655.
|
| 45 |
Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy[J]. Hepatology, 2013, 57(1): 399-408.
|
| 46 |
Huang G, Lai EC, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3): 490-505.
|
| 47 |
Chen CJ, Yang HI, Iloeje UH, et al. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B[J]. Hepatology, 2009, 49(5 Suppl): S72-S84.
|
| 48 |
Muthiah MD, Tan EY, Chua SHM, et al. Nucleoside analog monotherapy for prophylaxis in hepatitis B liver transplant patients is safe and efficacious[J]. Hepatol Int, 2020, 14(1): 57-69.
|
| 49 |
Delman AM, Ammann AM, Shah SA. The current status of virus-positive liver transplantation[J]. Curr Opin Organ Transplant, 2021, 26(2): 160-167.
|
| 50 |
Wong TC, Fung JY, Cui TY, et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis[J]. J Hepatol, 2019, 70(6)：1114-1122.
|
| 51 |
Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatology, 2017, 66(4): 1036-1044.
|
| 52 |
Kim JM, Joh JW, Kim SJ, et al. Steroid withdrawal in adult liver transplantation: occurrence at a single center[J]. Transplant Proc, 2010, 42(10): 4132-4136.
|
| 53 |
Lo CM, Lau GK, Chan SC, et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B[J]. Am J Transplant, 2007, 7(2): 434-439.
|
| 54 |
Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B[J]. J Hepatol, 2005, 43(2): 283-287.
|
| 55 |
Sánchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation[J]. Hepatology, 2000, 31(2): 496-501.
|
| 56 |
Duan BW, Tian LT, Lin DD, et al. Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection[J]. J Viral Hepat, 2019, 26 Suppl 1：85-89.
|
| 57 |
Zhou K, Zhou S. Risk of disease transmission in an expanded donor population: the potential of hepatitis B virus donors[J]. Curr Opin Organ Transplant, 2020, 25(6): 631-639.
|
| 58 |
Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management[J]. Am J Transplant, 2015, 15(5)：1162-1172.
|
| 59 |
Lu D, Yang F, Zhuo J, et al. The matching status between donor and recipient hepatitis B seroepidemiology makes a difference in liver transplantation for hepatocellular carcinoma[J]. Clin Transl Gastroenterol, 2020, 11(5): e00168.
|
| 60 |
Lee J, Park JY, Yang SJ, et al. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients[J]. J Viral Hepat, 2020, 27(8): 818-825.
|
| 61 |
Millson C, Considine A, Cramp ME, et al. Adult liver transplantation: UK Clinical Guideline - part 2: surgery and post-operation[J]. Frontline Gastroenterol, 2020, 11(5): 385-396.
|
| 62 |
Saab S, Song D, Challita YP, et al. Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B[J]. Clin Transplant, 2019, 33(12): e13740.
|
| 63 |
Sripongpun P, Mannalithara A, Kwo PY, et al. Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis[J]. Clin Gastroenterol Hepatol, 2020, 18(3)：747-749.
|
| 64 |
Rashidi-Alavijeh J, Straub K, Achterfeld A, et al. Safety and efficacy of tenofovir alafenamide in liver transplant recipients[J]. Transpl Infect Dis, 2021, 23(3): e13522.
|
| 65 |
Younossi ZM, Stepanova M, Sulkowski M, et al. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study[J]. Liver Int, 2017, 37(12): 1796-1804.
|
| 66 |
Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from ASTRAL-2 and -3 clinical trials[J]. Clin Infect Dis, 2016, 63(8): 1042-1048.
|
| 67 |
Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial[J]. J Hepatol, 2016, 65(1): 33-39.
|
| 68 |
Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(2): 122-132.
|
| 69 |
Levitsky J, Verna EC, O′Leary JG, et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients[J]. N Engl J Med, 2016, 375(21): 2106-2108.
|
| 70 |
Terrault NA, McCaughan GW, Curry MP, et al. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates[J]. Transplantation, 2017, 101(5): 945-955.
|
| 71 |
Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study[J]. Gastroenterology, 2015, 148(1): 100-107.
|
| 72 |
Ueda Y, Ikegami T, Akamatsu N, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience[J]. J Gastroenterol, 2017, 52(8): 986-991.
|
| 73 |
Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients[J]. J Hepatol, 2017, 67(3): 585-602.
|
| 74 |
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series[J]. J Hepatol, 2020, 73(5): 1170-1218.
|
| 75 |
Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation[J]. N Engl J Med, 2014, 371(25): 2375-2382.
|
| 76 |
Chen K, Man K, Metselaar HJ, et al. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation[J]. Liver Transpl, 2014, 20(3): 261-269.
|
| 77 |
Wei Q, Gao F, Zhuang R, et al. A national report from China Liver Transplant Registry: steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437.
|
| 78 |
Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634.
|
| 79 |
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1): 116-125.
|
| 80 |
Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(4): 411-419.
|
| 81 |
Foroncewicz B, Mucha K, Ryszkowska E, et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center[J]. Transplant Proc, 2009, 41(8): 3103-3106.
|
| 82 |
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5): 857-862.
|
| 83 |
Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients[J]. Liver Transpl, 2003, 9(2): 126-129.
|
| 84 |
Lee SG, Jeng LB, Saliba F, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of two randomized controlled trials[J]. Transplantation, 2021, 105(7): 1564-1575.
|
| 85 |
Rodríguez-Perálvarez M, Guerrero M, Barrera L, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplantation, 2018, 102(12)：2056-2064.
|
| 86 |
Grigg SE, Sarri GL, Gow PJ, et al. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10)：1260-1273.
|
| 87 |
Cholongitas E, Mamou C, Rodríguez-Castro KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review[J]. Transpl Int, 2014, 27(10)：1039-1049.
|
| 88 |
Saliba F, Dharancy S, Salamé E, et al. Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER registry[J]. Liver Transpl, 2020, 26(11)：1465-1476.
|
| 89 |
Xu SL, Zhang YC, Wang GY, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2016, 40(6): 674-681.
|
| 90 |
Tarantino G, Magistri P, Ballarin R, et al. Oncological impact of mTOR inhibitor immunosuppressive therapy after liver transplantation for hepatocellular carcinoma: review of the literature[J]. Front Pharmacol, 2016, 7: 387.
|
| 91 |
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
|
| 92 |
Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria[J]. Gastroenterology, 2012, 143(4)：986-994.
|
| 93 |
Bodzin AS, Lunsford KE, Markovic D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125.
|
| 94 |
Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294.
|
| 95 |
Verna EC, Patel YA, Aggarwal A, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant[J]. Am J Transplant, 2020, 20(2): 333-347.
|
| 96 |
Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma[J]. J Transplant, 2014, 2014: 913634.
|
| 97 |
Zhang Q, Chen H, Li Q, et al. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study[J]. Invest New Drugs, 2011, 29(6): 1360-1369.
|
| 98 |
Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy[J]. Exp Clin Transplant, 2010, 8(4): 307-313.
|
| 99 |
Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology, 2007, 45(2): 269-276.
|
| 100 |
de′Angelis N, Landi F, Nencioni M, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Prog Transplant, 2016, 26(4): 348-355.
|
| 101 |
Mancuso A, Mazzola A, Cabibbo G, et al. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis[J]. Dig Liver Dis, 2015, 47(4): 324-330.
|
| 102 |
Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation[J]. J Vasc Interv Radiol, 2010, 21(3): 333-338.
|
| 103 |
Iavarone M, Invernizzi F, Czauderna C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation[J]. Am J Transplant, 2019, 19(11)：3176-3184.
|
| 104 |
Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7)：970-973.
|